Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins

Marzieh Salehi; Benedikt A. Aulinger; David A. D'Alessio

doi:10.1210/er.2007-0031

Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins

Marzieh Salehi, Benedikt A. Aulinger, David A. D'Alessio

Research output: Contribution to journal › Review article › peer-review

93 Scopus citations

Abstract

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

Original language	English (US)
Pages (from-to)	367-379
Number of pages	13
Journal	Endocrine Reviews
Volume	29
Issue number	3
DOIs	https://doi.org/10.1210/er.2007-0031
State	Published - May 2008
Externally published	Yes

ASJC Scopus subject areas

Endocrinology
Endocrinology, Diabetes and Metabolism

Access to Document

10.1210/er.2007-0031

Cite this

@article{874e447a43eb425983b124d96e215053,

title = "Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins",

abstract = "Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.",

author = "Marzieh Salehi and Aulinger, {Benedikt A.} and D'Alessio, {David A.}",

year = "2008",

month = may,

doi = "10.1210/er.2007-0031",

language = "English (US)",

volume = "29",

pages = "367--379",

journal = "Endocrine Reviews",

issn = "0163-769X",

publisher = "The Endocrine Society",

number = "3",

}

TY - JOUR

T1 - Targeting β-cell mass in type 2 diabetes

T2 - Promise and limitations of new drugs based on incretins

AU - Salehi, Marzieh

AU - Aulinger, Benedikt A.

AU - D'Alessio, David A.

PY - 2008/5

Y1 - 2008/5

N2 - Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

AB - Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

UR - http://www.scopus.com/inward/record.url?scp=43549114067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549114067&partnerID=8YFLogxK

U2 - 10.1210/er.2007-0031

DO - 10.1210/er.2007-0031

M3 - Review article

C2 - 18292465

AN - SCOPUS:43549114067

SN - 0163-769X

VL - 29

SP - 367

EP - 379

JO - Endocrine Reviews

JF - Endocrine Reviews

IS - 3

ER -

Targeting β-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this